Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair

Rotator Cuff Tear Clinical Trial

Official title:

Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03149887
• Other study ID #: PRO17020089
• Status: Completed
• Phase: Phase 4
• Start date: December 5, 2017
• Est. completion date: March 1, 2019

Study information

• Verified date: January 2020
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, comparing standard care in the control group, with standard care plus the addition of injection of liposomal bupivacaine in the experimental group.

Description:

Arthroscopic rotator cuff repair is among the most painful of orthopedic surgeries (1-3). Hundreds of thousands of these procedures are carried out in the U.S. each year. Many involve the use of a brachial plexus nerve block, which serves to control pain for 12 to 14 hours. However, when the block wears off, many patients are left with severe pain. (4-5) This severe pain must then be managed at home with oral opioids, which have numerous undesirable side effects, and may lead to chronic opioid dependence. Thus, any therapy which might reduce the pain burden on these patients and therefore reduce opioid use and side effects, would be advantageous.

Recently, a long-acting form of bupivacaine, prepared in liposomes, has been approved for use by injection in the surgical field, though not for peripheral nerve blockade (6). The drug has been used to improve postoperative pain after total knee arthroplasty and total hip arthroplasty when injected in the peri-articular tissues by the orthopedist (7-12), as well as in other surgeries, both orthopedic and non-orthopedic.(13-16) Unfortunately, preliminary studies utilizing liposomal bupivacaine as the injectate in peripheral nerve blocks have been disappointing, largely because the gradual release of the drug did not permit establishment of effective nerve blockade; it appears to be more effective in the role of analgesic as opposed to anesthetic (17).

In addition to lower extremity orthopedic procedures, liposomal bupivacaine has also been demonstrated to reduce pain after shoulder arthroplasty (joint replacement), a similarly painful shoulder procedure. Liposomal bupivacaine is FDA approved for administration into surgical sites to produce postsurgical analgesia and mitigate pain, but it hasn't been evaluated yet as an intervention to provide analgesia for rotator cuff surgery, though the pain mechanisms for these two procedures, including joint capsule violation and boney intervention are likely similar.

In this prospective, comparative, randomized, double blinded, placebo controlled trial, we propose to provide standard therapy for both groups of patients, consisting of interscalene block with 16 ml of standard 0.5% bupivacaine, as well as propofol infusion to provide general anesthesia in the operating room and low doses of ketamine for analgesia. In addition, half of the patients will receive an injection of 266 mg liposomal bupivacaine (FDA approved dosage) into the subacromial space and peri-articular tissues at the end of surgery. The other half of the patients will receive an injection of an inert solution of comparable volume into the peri-articular tissues at the conclusion of surgery (control group).

The primary outcome measure is pain score at the time of block resolution, as noted by patients when called at 24 hours after surgery. Secondary outcomes include maximal pain score on postoperative day 1, 2 and 3, total oral opioid morphine equivalent after 3 days, and occurrence of typical opioid side effects (nausea, vomiting, drowsiness). In addition to follow up phone call on postoperative day 1, patients will keep a pain diary, documenting pain scores and opioid use for the first 72 hours, which will be collected by the surgeon in his office at the first postoperative visit. Any adverse occurrences related to nerve blockade or prolonged bupivacaine effect will also be recorded.

We expect to enroll 25 patients in each group (total of 50). Sample size is based upon the a priori assumption that liposomal bupivacaine will result in reduced pain scores by at least 2 units on the NRS scale at the time of nerve block resolution. Inclusion criteria include adult patients, undergoing rotator cuff repair as outpatients at our facility, ASA physical status category 1 through 3. Exclusion criteria include inability to receive local anesthetic medications for any reason, contraindications to peripheral nerve block (coagulopathy, patient refusal, local infection and pre-existing nerve injury or dysfunction in the operative arm), chronic opioid dependence, pregnancy and pediatric age group. This study will involve anesthesiology, orthopedics, physical therapy, pain management and the center for translational science institute at the University of Pittsburgh.

References:

1. Kim CW, Kim JH, Kim DG. The factors affecting pain pattern after arthroscopic rotator cuff repair. Clin Orthop Surg. 2014;6:392-400.

2. Uquillas CA, Capogna BM, Rossy WH, Mahure SA, Rokito AS. Post operative pain control after arthrosopic rotator cuff repair. Review JSES 2016.25(7): 1204-13.

3. Shin SJ, Do NH, Lee J, Ko YW. Efficacy of a subacromial corticosteroid injection for persistent pain after arthroscopic rotator cuff repair. Am J Sports Med 2016. 44(9):2231-6.

4. Abdallah FW, Halpern SH, Aoyama K, Brull R. Will the real benefits of single-shot interscalene block please stand up? A systematic review and meta-analysis. Anesth Analg. 2015. 120(5):1114-29.

5. Mifune Y, Inui A, Nagura I, Sakata R, Muto T, Harada Y, TAkase F, Kurosaka M, Kokubu T. Application of pain quantitative analysis device for assessment of post operative pain after arthroscopic rotator cuff repair. Open Orthoped J. 2015.9:89-93.

6. Ilfeld BM. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. Exp Opin Pharm. 2013. 14(17):2421-31.

7. Iorio R. The role of liposomal bupivacaine in vale-based care. Am J Ortho. 2016. 45(7):S13-S17.

8. Sporer SM, Rogers T. Postoperative pain management after primary total knee arthroplasty: The value of liposomal bupivacaine. J Arthroplasty. 2016. 31(11):2603-2607.

9. Chugtai M, Cherian JJ, Mistry JB, Elmallah RD, Bennett A, Mont MA. Liposomal bpuivicaine suspension can reduce lengths of stay and improve discharge status of patients undergoing total knee arthroplasty. J Knee Surg. 2016. 29(5):e3

10. Yu SW, Szulc AL, Walton SL, Davidovitch RI, Bosco JA, Iorio R. Liposomal bupivacaine as an adjunct to postoperative pain control in total hip arthroplasty. J Arthroplasty. 2016. 31(7):1510-5.

11. Cien AJ, Penny PC, Horn BJ, Popovich JM, Taunt CJ. Comparison between liposomal bupivicane and femoral nerve block in patients undergoing primary total knee arthroplasty. J Surg Orthop Adv. 2015. 24(4):225-9.

12. Barrington JW, Olugbode O, Lovald S, Ong K, Watson H, Emerson RJ. Liposomal bupivacaine:

A comparative study of more than 1000 total joint arthroplasty cases. Orthoped Clin Na. 2015. 46(4):469-77.

13. Robbins J. Green CL. Parekh SG. Liposomal bupivacaine in forefoot surgery. Foot Ankle Int. 2015. 36(5):503-7.

14. Huh J, Parekh SG. Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct. J Surg Orthop Adv.2014. 23(4):198-202.

15. Hutchins JL, Kesha R, Blanco F, Dunn T, Hochhalter R. Ultrasound-guided subcostal transversus abdominus plane blocks with liposomal bupivacaine vs. non-liposomal bupivacaine for posteropative pain control after laparoscopic hand-assisted donor nephrectomy: a prospective randomized observer-blinded study. Anaesthesia. 2016. 71(7):930-7.

16. Miranda SG, Liu Y, Morrison SD, Sood RF, Gallagher T, Gougoutas AJ, Colohan SM, Loui O, Mathes DW, Neligan PC, Said HK. Improved health care economic outcomes after liposomal bupivacaine administration in first-stage breast reconstruction. J Plast Reconstr Aesthet Surg. 2016. 69(10):1456-7.

17. Ilfeld BM, Malhotra N

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: March 1, 2019
• Est. primary completion date: February 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adult patients up to age 65 years, undergoing elective, ambulatory, arthroscopic rotator cuff repair.

Exclusion Criteria:

• Pregnancy, coagulopathy, allergy to bupivacaine, renal failure, hepatic insufficiency, and/or inappropriate candidate for usual therapy (specifically, if unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block).

Related Conditions & MeSH terms

• Rotator Cuff Injuries
• Rotator Cuff Tear

Intervention

Drug:
• Liposomal bupivacaine
Liposomal bupivacaine solution (Exparel) for injection
• Placebo
Inert solution created to appear as liposomal bupivacaine (Exparel) for injection

Locations

Country	Name	City	State
United States	University of Pittsburgh Medical Center-Southside/Mercy	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Steven Orebaugh	Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Numeric Rating Pain Score [NRS] at Time of Block Resolution	Numeric rating score pain level at time of nerve block resolution, on scale of 0-10, as reported by patient at time of 24 hour follow up phone call. A reported score of zero implies no pain, whereas a score of "10" implies very severe pain. Outcome score is mean of reported pain scores by participants at time of nerve block resolution.	At the time of block resolution, as reported by patients at follow up phone call
Secondary	Mean NRS Pain Score at Rest on Postoperative Day 1	Mean NRS pain score on scale of 1-10, at rest (zero is no pain, 10 is severe pain). Patients recorded their pain score at rest with administration of each oral analgesic tablet. Outcome score is mean of reported pain scores for this day.	Postoperative day 1
Secondary	Mean NRS Pain Score at Rest on Postoperative Day 2	Mean of patient-reported NRS pain scores on postoperative day 2. Patients recorded pain scores at rest with each oral analgesic tablet taken. Zero implies no pain, whereas a score of 10 translates to very severe pain. Outcome score is mean of reported pain scores for this day.	Postoperative day 2
Secondary	Mean NRS Pain Scores at Rest on Postoperative Day 3	Patients recorded their pain scores at rest with ingestion of each oral analgesic table on postoperative day 3. Zero implies no pain, whereas 10 implies very severe pain. Outcome score is mean of reported pain scores for this day.	Postoperative Day 3
Secondary	Mean NRS Pain Score With Motion	NRS Pain score with passive motion (for those patients who performed this), on 0-10 scale, with zero being no pain and 10 representing severe pain. Outcome score is mean of reported pain scores for passive motion episodes on all three postoperative days.	Mean value of reported pain scores on postoperative days 1,2 and 3
Secondary	Oral Analgesic Requirements on Postoperative Day 1	Oral analgesic dose (5 mg oxycodone tablets) required expressed as oral morphine equivalents. Outcome is total oral opioid used on postoperative day 1 expressed as oral morphine equivalents in mg.	Postoperative day 1
Secondary	Oral Analgesic Requirements on Postoperative Day 2	Amount of oral opioids (oxycodone 5 mg tablets) ingested by patients on Postoperative Day 2, expressed as Oral Morphine Equivalents in mg.	Postoperative day 2
Secondary	Oral Analgesic Requirements on Postoperative Day 3	Patients reported the number of oral analgesic tablets (5 mg oxycodone tablets) ingested on postoperative day 3. This is expressed as Oral Morphine Equivalents in mg.	Postoperative Day 3